Serum placental protein 14: A novel marker of selective oestrogen receptor modulator action on the postmenopausal endometrium

Biomarkers

Volumn 7, Issue 3, 2002, Pages 257-266

  Tankó, László ^a   Warming, Lise ^a   Bagger, Yu Z ^a   Byrjalsen, Inger ^a   Jensen, Susi ^a   Christiansen, Claus ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Endometrial adverse events; Levormeloxifene; Postmenopausal women; Raloxifene; Serum placental protein 14

Indexed keywords

BIOLOGICAL MARKER; CENTCHROMAN; PLACEBO; PLACENTA PROTEIN 14; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; GLYCOPROTEIN; PAEP PROTEIN, HUMAN; PLACENTA PROTEIN; PYRROLIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BIOLOGICAL MONITORING; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EDEMA; ENDOMETRIUM; ENDOMETRIUM CELL; FEMALE; GYNECOLOGIC DISEASE; HUMAN; HYSTEROSCOPY; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; THICKNESS; TRANSVAGINAL ECHOGRAPHY; VASCULARIZATION; ANALYSIS OF VARIANCE; BLOOD; BONE DENSITY; COMPARATIVE STUDY; DRUG EFFECT; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TIME; UTERUS; VAGINA;

ADULT; ANALYSIS OF VARIANCE; BONE DENSITY; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOMETRIUM; ENDOSONOGRAPHY; FEMALE; GLYCOPROTEINS; HUMAN; MIDDLE AGE; POSTMENOPAUSE; PREGNANCY PROTEINS; PYRROLIDINES; RADIOIMMUNOASSAY; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS; UTERUS; VAGINA; HUMANS; MIDDLE AGED;

EID: 0035992104     PISSN: 1354750X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13547500210125031     Document Type: Article

References (23)

1. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy
2. Uterine side effects of treatment with tamoxifen
3. Secretory proteins of the endometrium - Potential markers for endometrial dysfunction
4. Ultrasonographic appearance of endometrium in postmenopausal breast cancer patients receiving tamoxifen
5. The measurement of secretory endometrial protein PP14 in serum from postmenopausal women receiving unopposed estrogen or continuously combined estrogen/progestogen
6. Sequential estrogen and progesteron therapy: Assessment of progestational effects on the postmenopausal endometrium
7. The endometrial effects of SERMs
8. Assessment of hormonally active agents in the reproductive tract of female nonhuman primates
9. Selective oestrogen receptor modulators: Clinical spectrum
10. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
11. Effects of tamoxifen and ICI 164384 on protein synthesis and vectorial secretion in polarized rat uterine epithelial cells
12. The demography of menopause
13. Estrogen regulation of protein synthesis in the immature rat uterus: The analysis of proteins released into the medium during in vitro incubation
14. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women
15. Selective estrogen receptor modulators: A look ahead
16. Transvaginal ultrasonography and hysteroscopy in the diagnosis of endometrial abnormalities
17. A prospective randomized controlled study comparing the morphological and biochemical responses of the endometrium to two different forms of 'period-free' hormone replacement therapy
18. ET and histological abnormalities in women on hormonal replacement therapy: A transvaginal ultrasonography/hysteroscopic study
19. Selective estrogen receptor modulators (SERMs) in clinical practice
20. The post-menopausal uterus: The effect of hormone replacement therapy on the serum levels of secretory endometrial protein PP14/beta-lactoglobulin homologue
21. Endometrial proteins
22. Antiestrogen stimulation of the production of a 37,000 molecular weight secreted protein and estrogen stimulation of the production of a 32,000 molecular weight secreted protein in MCF-7 human breast cancer cells
23. Molecular effects of antiestrogens (tamoxifen and LY117018) on estrogen-dependent glycoprotein (USP-1) synthesized and secreted by rat uterine epithelial cells